Maxcyte earnings release, August 12, 2026

Maxcyte, Inc. (MXCT) · Form 8-K, Item 2.02 · Filed · SEC filing

​

MaxCyte Reports Second Quarter 2026 Financial Results

ROCKVILLE, MD, August 12, 2026 — MaxCyte, Inc. (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced its second quarter ended June 30, 2026 financial results and reiterated its 2026 guidance.

"We are pleased with our second quarter results, which were ahead of our expectations, driven by execution on instrument placements and stability in processing assembly sales," said Maher Masoud, President and CEO of MaxCyte. "A significant development for MaxCyte was the recent signing of our first multi-platform technology license partnership with large pharma, an enterprise-level agreement with Genentech that we believe will unlock meaningful new opportunities for MaxCyte. Separately, our SPL portfolio remains a key driver of long-term value as evident by growing commercial royalty revenue and the advancement of a significant number of SPL programs through the clinic. Lastly, our goal has been to return to revenue growth while reducing our net losses. In the first half of 2026, we delivered a meaningful reduction in net loss and expect to benefit further as we continue to execute against our plan and return to revenue growth.”

Second Quarter Financial Results

​¹

Full Year 2026 Guidance

The following tables provide details regarding the sources of our revenue for the periods presented.

​

​

Webcast and Conference Call Details

MaxCyte will host a conference call today, August 12, 2026, at 4:30 p.m. Eastern Time.

Investors interested in listening to the conference call are required to register online. A live and archived webcast of the event will be available on the "Events" section of the MaxCyte website at https://investors.maxcyte.com/.

​²

About MaxCyte

At MaxCyte®, we are committed to building better cells together. As a leading cell-engineering company, we are driving the discovery, development and commercialization of next-generation cell therapies. Our best-in-class Flow Electroporation® technology and SeQure™ gene editing risk assessment services enable high-performance cell engineering and rigorous evaluation of editing outcomes, supporting confidence in therapeutic development. Supported by expert scientific, technical and regulatory guidance, our platform empowers researchers to engineer diverse cell types and payloads, accelerating the development of safe and effective treatments for human health. For more than 25 years, we've been advancing cell engineering, shaping the future of medicine.

Learn more at maxcyte.com and follow us on LinkedIn and Bluesky.

Non-GAAP Financial Measures

This press release contains EBITDA, which is a non-GAAP measure defined as earnings before interest income and expense, taxes, depreciation and amortization. MaxCyte believes that EBITDA provides useful information to management and investors relating to its results of operations. The Company's management uses these non-GAAP measures to compare the Company's performance to that of prior periods for trend analyses, and for budgeting and planning purposes. The Company believes that the use of EBITDA provides an additional tool for investors to use in evaluating ongoing operating results and trends and in comparing the Company's financial measures with other companies, many of which present similar non-GAAP financial measures to investors, and that it allows for greater transparency with respect to key metrics used by management in its financial and operational decision-making.

This press release also contains Non-GAAP Gross Margin, which we define as Gross Margin when excluding SPL program related revenue and reserves for excess and obsolete inventory. The Company believes that the use of Non-GAAP Gross Margin provides an additional tool to investors because it provides consistency and comparability with past financial performance, as Non-GAAP Gross Margin excludes non-core revenues and inventory reserves, which can vary significantly between periods and thus affect comparability.

Management does not consider these Non-GAAP financial measures in isolation or as an alternative to financial measures determined in accordance with GAAP. The principal limitation of these Non-GAAP financial measures is that they exclude significant revenues and expenses that are required by GAAP to be recorded in the Company's financial statements. In order to compensate for these limitations, management presents these Non-GAAP financial measures along with GAAP results. Non-GAAP measures should be considered in addition to results prepared in accordance with GAAP, but should not be considered a substitute for, or superior to, GAAP results. Reconciliation tables of net loss, the most comparable GAAP financial measure, to EBITDA, and Gross Margin, the most comparable GAAP financial measure, to Non-GAAP Gross Margin, are included at the end of this release. MaxCyte urges investors to review the reconciliation and not to rely on any single financial measure to evaluate the Company's business.

Financial statements

Income Statement

Three Months Ended — The following tables provide details regarding the sources of our revenue for the periods presented. (in thousands, except percentages)

Three Months Ended – June 30 (Unaudited) – 2026Three Months Ended – June 30 (Unaudited) – 2025%
Instruments1,7612,141-18.0%
PAs and Consumables2,3373,128-25.0%
Licenses1,8222,619-30.0%
Assay Service24551380.0%
Other33825931.0%
Total Core Revenue6,5038,198-21.0%
Milestones440.0%
Royalties764305150.0%
Total Revenue7,2718,507-15.0%

Income Statement

Three Months Ended June 30, — (in thousands, except share and per share amounts)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Revenue7,2718,50716,92218,897
Cost of goods sold1,6751,5193,2443,016
Gross profit5,5966,98813,67815,881
Operating expenses:Research and development4,2536,2698,11012,172
Operating expenses:Sales and marketing3,3645,7866,79211,484
Operating expenses:General and administrative7,2588,08013,22416,606
Operating expenses:Depreciation and amortization9531,0801,9692,141
Operating expenses:Total operating expenses15,82821,21530,09542,403
Operating expenses:Operating loss-10,232-14,227-16,417-26,522
Other income:Interest income1,3581,8702,7933,904
Other income:Total other income1,3581,8702,7933,904
Other income:Net loss-8,874-12,357-13,624-22,618
Other income:Basic and diluted net loss per share-0.08-0.12-0.13-0.21
Other income:Weighted-average shares outstanding, basic and diluted106,822,633106,403,540106,848,715106,178,262

Income Statement

Three months ended June 30, 2026 — (Unaudited)

Three months ended June 30, 2026 – GAAPThree months ended June 30, 2026 – AdjustmentsThree months ended June 30, 2026 – Non-GAAPThree months ended June 30, 2025 – GAAPThree months ended June 30, 2025 – AdjustmentsThree months ended June 30, 2025 – Non-GAAP
Revenue7,271-7686,5038,507-3098,198
Cost of Goods Sold1,675-1821,4931,519-1001,419
Gross Margin5,596-5865,0106,988-2096,779
Gross Margin %77.0%7782.0%83

Income Statement

Six months ended June 30, 2026 — (Unaudited)

Six months ended June 30, 2026 – GAAPSix months ended June 30, 2026 – AdjustmentsSix months ended June 30, 2026 – Non-GAAPSix months ended June 30, 2025 – GAAPSix months ended June 30, 2025 – AdjustmentsSix months ended June 30, 2025 – Non-GAAP
Revenue16,922-4,20112,72118,897-2,45616,441
Cost of Goods Sold3,244-3792,8653,016-1652,851
Gross Margin13,678-3,8229,85615,881-2,29113,590
Gross Margin %81.0%7784.0%83

Balance Sheet

December 31, — (in thousands, except share and per share amounts)

June 30, – 2026December 31, – 2025
Current assets:Cash and cash equivalents15,04220,065
Current assets:Short-term investments, at amortized cost90,64882,979
Current assets:Accounts receivable, net3,9223,503
Current assets:Inventory, net7,7987,547
Current assets:Prepaid expenses and other current assets3,6644,275
Current assets:Assets held for sale200
Current assets:Total current assets121,274118,369
Current assets:Investments, non-current, at amortized cost36,23352,570
Current assets:Property and equipment, net14,89717,531
Current assets:Right-of-use asset - operating leases10,47210,920
Current assets:Intangible assets, net766650
Current assets:Other assets1,0302,467
Current assets:Total assets184,672202,507
Current liabilities:Accounts payable1,7341,401
Current liabilities:Accrued expenses and other4,1707,812
Current liabilities:Operating lease liability, current1,5281,456
Current liabilities:Deferred revenue, current portion2,4633,598
Current liabilities:Total current liabilities9,89514,267
Current liabilities:Operating lease liability, net of current portion15,72316,487
Current liabilities:Other liabilities302263
Current liabilities:Total liabilities25,92031,017
Stockholders' equity:Common stock, $0.01 par value; 400,000,000 shares authorized, 107,447,077 and 106,789,618 shares issued, and 106,134,011 and 106,789,618 outstanding at June 30, 2026 and December 31, 2025, respectively1,0741,068
Stockholders' equity:Additional paid-in capital434,263431,905
Stockholders' equity:Treasury stock, 1,313,066 shares, at cost-1,478
Stockholders' equity:Accumulated deficit-275,107-261,483
Stockholders' equity:Total stockholders' equity158,752171,490
Stockholders' equity:Total liabilities and stockholders' equity184,672202,507

Cash Flow

Six Months Ended June 30, — (in thousands)

Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Cash flows from operating activities:Net loss-13,624-22,618
Adjustments to reconcile net loss to net cash used in operating activities:Depreciation and amortization2,0252,196
Adjustments to reconcile net loss to net cash used in operating activities:Impairment of fixed assets630
Adjustments to reconcile net loss to net cash used in operating activities:Lease right-of-use asset amortization448378
Adjustments to reconcile net loss to net cash used in operating activities:Net book value of consigned equipment sold10255
Adjustments to reconcile net loss to net cash used in operating activities:Loss on disposal of property and equipment22113
Full release

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements about us and our industry involve substantial known and unknown risks, uncertainties, and assumptions, including those

​³... (truncated)y and plans, customer expectations and objectives of management for future operations, are forward-looking statements. Forward-looking statements include, but are not limited to, statements about possible or future results of operations or financial position. In some cases, you can identify forward-looking statements because they contain words such as "may," "might," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "seek," "predict," "future," "project," "potential," "continue," "contemplate," "target," the negative of these words and similar words or expressions. These statements are inherently uncertain, and investors are cautioned not to unduly rely on these statements. The forward-looking statements contained in this press release, include, without limitation, our full year 2026 revenue and cash guidance, statements concerning the following: our expected future growth and success of our business model; the size and growth potential of the markets for our products, and our ability to serve those markets, increase our market share, and achieve and maintain industry leadership; our ability to expand our customer base and enter into additional SPL partnerships; expectations regarding customer-level activities (including the expected advancement of our SPL partners' clinical programs, including Phase 3 trial initiations); the timing and amount of any share repurchases under our share repurchase program; our financial performance and capital requirements; the adequacy of our cash resources and availability of financing on commercially reasonable terms; our expectations regarding general market and economic conditions that may impact investor confidence in the biopharmaceutical industry and affect the amount of capital such investors provide to our current and potential partners; and our use of available capital resources.

​

These and other risks and uncertainties are described in greater detail in Item 1A , entitled "Risk Factors," in our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission, as well as in discussions of potential risks, uncertainties, and other important factors in the other filings that we make with the Securities and Exchange Commission from time to time. These documents are available through the Investor Menu, Financials section, under "SEC Filings" on the Investors page of our website at http://investors.maxcyte.com. Any forward-looking statements in this press release are based on our current beliefs and opinions on the relevant subject based on information available to us as of the date of such press release, and you should not rely on forward-looking statements as predictions of future events. We undertake no obligation to update any forward-looking statements made in this press release to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.

​

MaxCyte Contacts:

​

US IR Adviser

Gilmartin Group

Erik Abdow ir@maxcyte.com

​

Media Contact

Oak Street Communications

Kristen White

​ kristen@oakstreetcommunications.com

415.608.6060

​

​⁴

MaxCyte, Inc.

Unaudited Condensed Consolidated Balance Sheets

(in thousands, except share and per share amounts)

​

​

​⁵

MaxCyte, Inc.

Unaudited Condensed Consolidated Statements of Operations

(in thousands, except share and per share amounts)

​

​

​⁶

MaxCyte, Inc.

Unaudited Condensed Consolidated Statements of Cash Flows

(in thousands)

​⁷

Unaudited Reconciliation of Net Loss to EBITDA

(in thousands)

(Unaudited)

​

​

​⁸

Unaudited Reconciliation of Gross Margin to Non-GAAP Adjusted Gross Margin

(in thousands, except for percentages)

(Unaudited)

​

​

​

​⁹

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Maxcyte earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.